info@ida.gen.tr

Plasma H羹cre Antikorlar覺 Geri

  • Clonalpath™ and Clonalpath™-Plus have been designed for an optimal differentiation between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) based on the percentage of immunophenotypically normal plasma cells. Pathological plasma cells can be differentiated from normal plasma cells according to their immunophenotypic pattern of expression of anti-CD19, CD56, CD45 and CD38.

    Clonalpath™ contains the following antibody combination for the identification and characterization of plasma cells in a single vial:

    FITC
    PE
    PE-Cyanine5
    CD38
    CD56
    CD19

    Clonalpath™-Plus includes anti-CD45 antibody that is very useful for characterization of normal and pathological plasma cells:

    FITC
    PE
    PE-Cyanine5
    APC
    CD38
    CD56
    CD19
    CD45
     

襤LG襤N襤Z襤 EKEB襤LECEK RNLER